2-Nitro-4-methoxy-benzolsulfonsaeure-amid | 81792-84-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Nitro-4-methoxy-benzolsulfonsaeure-amid
• 英文别名: 4-Methoxy-2-nitro-benzol-sulfonsaeure-(1)-amid；4-Methoxy-2-nitrobenzolsulfonamid；4-Methoxy-2-nitrobenzenesulfonamide
• CAS: 81792-84-9
• 化学式: C₇H₈N₂O₅S
• 分子量: 232.217
• InChiKey: MELAWMCOLMMBNG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  124
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-Nitro-4-methoxy-benzolsulfonsaeure-amid 在 铁粉 、 溶剂黄146 作用下， 生成 2-氨基-4-甲氧基-苯磺酰胺
  参考文献：
  名称：

  Hypoglycaemic Agents. Part III

  摘要：

  描述了托布唑胺的新变体。

  DOI：

  10.1111/j.2042-7158.1962.tb11132.x
• 作为产物：
  描述：

  4-Methoxy-(2-nitro-phenyl)-benzylsulfid 在 ammonium hydroxide 、 水 、 氯 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 0.75h， 生成 2-Nitro-4-methoxy-benzolsulfonsaeure-amid
  参考文献：
  名称：

  Inhibitors of HCV NS5B polymerase: Synthesis and structure–activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring

  摘要：

  A series of non-nucleoside HCV NS5B polymerase inhibitors based on the N-1-benzyl or N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine core substituted in the D-ring aromatic moiety have been prepared and evaluated. Aromatic substituents extending from position 7 of the D-ring exhibited excellent potency against both genotypes 1a and 1b. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.022

文献信息

• Ccr4 antagonist and medical use thereof
  申请人：Habashita Hiromu

  公开号：US20060004010A1

  公开（公告）日：2006-01-05

  A compound of formula (I) or a salt thereof, and medical use thereof (the symbols in the formula are as described in the specification). The compound of formula (I) has CCR4 antagonistic activity, and therefore is useful as a preventive and/or therapeutic agent for diseases associated with CCR4, i.e., CCR4-mediated diseases such as inflammatory and/or allergic diseases [e.g., systemic inflammatory response syndrome (SIRS), anaphylaxis or anaphylaxis-like reaction, allergic vasculitis, reject reaction for graft organ, hepatitis, nephritis, nephrosis, pancreatitis, rhinitis, arthritis, inflammatory ocular diseases, inflammatory bowel diseases, diseases in cerebro and/or circulatory system, respiratory diseases, dermatic diseases, autoimmune diseases, etc.], and the like.

  化合物式（I）或其盐，并且其医疗用途（式中的符号如说明书所述）。化合物式（I）具有CCR4拮抗活性，因此可用作预防和/或治疗CCR4相关的疾病的药物，即CCR4介导的疾病，例如炎症和/或过敏性疾病[例如全身炎症反应综合征（SIRS），过敏性休克或类似休克反应，过敏性血管炎，移植器官排斥反应，肝炎，肾炎，肾病综合征，胰腺炎，鼻炎，关节炎，炎症性眼部疾病，炎症性肠病，大脑和/或循环系统疾病，呼吸系统疾病，皮肤疾病，自身免疫性疾病等]等。
• CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME
  申请人：THE CENTRE FOR DRUG RESEARCH AND DEVELOPMENT

  公开号：US20140315954A1

  公开（公告）日：2014-10-23

  Compounds having cytotoxic and/or anti-mitotic activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-(D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having structure (I).

  公开了具有细胞毒性和/或抗有丝分裂活性的化合物。这些化合物具有以下结构（I）：包括立体异构体、药学上可接受的盐和其前药，其中R1、R2、R3、R4和R5如本文所定义。公开了与制备和使用此类化合物相关的方法，以及包含此类化合物的制药组合物。还公开了具有结构：（T）-（L）-（D）的组合物，其中（T）是靶向基团，（L）是可选的连接剂，而（D）是具有结构（I）的化合物。
• Dithionite-Mediated Tandem Nitro Reduction/Imine Formation/Intramolecular Cyclization for the Synthesis of Dihydro-benzothiadiazine-1,1-dioxides
  作者：Joydev K. Laha、Pankaj Gupta、Amitava Hazra

  DOI：10.1021/acs.joc.3c01844

  日期：2024.1.5

  A one-pot, tandem reductive annulation of 2-nitrobenzenesulfonamides with aldehydes to the synthesis of substituted 3,4-dihydro-2H-1,2,4-benzothiadiazine-1,1-dioxides in the presence of sodium dithionite (Na2S2O4) is reported under mild conditions. The method involves in situ reduction of the nitro group followed by condensation with aldehydes to form an imine, which upon subsequent intramolecular cyclization

  2-硝基苯磺酰胺与醛的一锅串联还原成环反应，在连二亚硫酸钠 ( Na 2在温和条件下报告了S 2 O 4 )。该方法涉及硝基的原位还原，然后与醛缩合形成亚胺，亚胺随后进行分子内环化，在一锅条件下形成产物。该方案具有使用廉价的Na 2 S 2 O 4作为专用试剂、显着的官能团耐受性、广泛的底物范围、高产物产量和可扩展性的特点。
• CCR4 ANTAGONIST AND MEDICINAL USE THEREOF
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1541563A1

  公开（公告）日：2005-06-15

  A compound of formula (I) or a salt thereof, and medical use thereof (the symbols in the formula are as described in the specification). The compound of formula (I) has CCR4 antagonistic activity, and therefore is useful as a preventive and/or therapeutic agent for diseases associated with CCR4, i.e., CCR4-mediated diseases such as inflammatory and/or allergic diseases [e.g., systemic inflammatory response syndrome (SIRS), anaphylaxis or anaphylaxis-like reaction, allergic vasculitis, reject reaction for graft organ, hepatitis, nephritis, nephrosis, pancreatitis, rhinitis, arthritis, inflammatory ocular diseases, inflammatory bowel diseases, diseases in cerebro and/or circulatory system, respiratory diseases, dermatic diseases, autoimmune diseases, etc.], and the like.

  式 (I) 的化合物或其盐及其医疗用途（式中符号如说明书所述）。 式（I）化合物具有 CCR4 拮抗活性，因此可用作与 CCR4 相关疾病的预防和/或治疗剂，即 CCR4 介导的疾病，如炎症性和/或过敏性疾病[如、全身炎症反应综合征（SIRS）、过敏性休克或过敏性休克样反应、过敏性血管炎、移植器官排斥反应、肝炎、肾炎、肾病、胰腺炎、鼻炎、关节炎、炎症性眼病、炎症性肠病、脑和/或循环系统疾病、呼吸系统疾病、皮肤病、自身免疫性疾病等]等。
• Cytotoxic and anti-mitotic compounds, and methods of using the same
  申请人：ZYMEWORKS INC.

  公开号：US10201614B2

  公开（公告）日：2019-02-12

  Compounds having cytotoxic and/or anti-mitotic activity are disclosed. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. Also disclosed are compositions having the structure: (T)-(L)-D), wherein (T) is a targeting moiety, (L) is an optional linker, and (D) is a compound having cytotoxic and/or anti-mitotic activity.

  本研究公开了具有细胞毒性和/或抗有丝分裂活性的化合物。还公开了与制备和使用此类化合物相关的方法，以及包含此类化合物的药物组合物。还公开了具有以下结构的组合物：(T)-(L)-D)，其中(T)是靶向分子，(L)是任选连接体，(D)是具有细胞毒性和/或抗有丝分裂活性的化合物。